Adherence to Post-Stroke Pharmacotherapy: Scale Validation and Correlates among a Sample of Stroke Survivors.
adherence
medication
pharmacotherapy
post-stroke
quality of life
stroke
stroke survivors
validated scale
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
16 Aug 2022
16 Aug 2022
Historique:
received:
05
07
2022
revised:
06
08
2022
accepted:
12
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Background and Objectives: Adherence to post-stroke pharmacotherapy has been less studied compared with other cardiovascular diseases, and previous research in this context utilized generic tools without cross-validating for stroke specific factors and patient characteristics. This study aimed to validate the Lebanese Medication Adherence Scale (LMAS-14) among stroke survivors to assess adherence to post-stroke pharmacotherapy. It also aimed to determine the socioeconomic, clinical characteristics, and health related quality of life correlates of medication adherence among stroke survivors. Materials and Methods: This was a cross-sectional study that included stroke survivors from districts throughout Lebanon. A well-structured questionnaire consisting of three parts was developed and utilized to collect data. The first part included questions about the sociodemographic and socioeconomic characteristics. The second part included questions about medical history, current clinical characteristics of the patients, and use of medications. The third part included validated scales to assess stroke outcomes, daily performance and activities, and quality of life. Results: A total of 172 stroke survivors were included. The LMAS-14 structure was validated over a solution of three factors, with a Kaiser−Meyer−Olkin (KMO) measure of sampling adequacy = 0.836 and a significant Bartlett’s test of sphericity (p < 0.001). Severe difficulty in obtaining medications within the current Lebanese economic crisis was significantly associated with lower medication adherence (Beta = −8.473, p = 0.001). Lower medication adherence was also associated with poor stroke prognosis (Beta = −3.264, p = 0.027), higher number of used medications (Beta = −0.610, p = 0.034), and longer duration of stroke diagnosis (Beta = −4.292, p = 0.002). Conclusions: The LMAS−14 is a valid and reliable tool to assess medication adherence in stroke practice and research. Severe difficulty in obtaining medications due to unpredictable availability and shortage of supplies is associated with lower medication adherence, and thus places stroke survivors at higher risk of complications and morality. Additional measures and urgent action by stroke care providers and public health stakeholders are necessary to ensure adequate post-stroke management and outcomes.
Identifiants
pubmed: 36013576
pii: medicina58081109
doi: 10.3390/medicina58081109
pmc: PMC9413934
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Stroke. 2000 Dec;31(12):2995-3000
pubmed: 11108762
Int J Med Educ. 2011 Jun 27;2:53-55
pubmed: 28029643
Chest. 2006 Jul;130(1 Suppl):65S-72S
pubmed: 16840369
Stroke. 1996 Sep;27(9):1467-72
pubmed: 8784114
Adv Ther. 2004 Jul-Aug;21(4):214-31
pubmed: 15605616
Stroke. 1992 Apr;23(4):527-31
pubmed: 1561684
NeuroRehabilitation. 2019;44(2):283-293
pubmed: 31006693
Health Econ Rev. 2022 Apr 11;12(1):24
pubmed: 35403980
Saudi Pharm J. 2015 Jan;23(1):33-40
pubmed: 25685041
Int J Clin Pharm. 2021 Aug;43(4):918-927
pubmed: 33201490
Ethn Dis. 2009 Winter;19(1):1
pubmed: 19341154
Lancet Oncol. 2021 Aug;22(8):1063
pubmed: 34246331
BMC Cardiovasc Disord. 2020 Feb 11;20(1):71
pubmed: 32046646
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
Clin Geriatr Med. 2012 May;28(2):287-300
pubmed: 22500544
Arch Phys Med Rehabil. 2006 Sep;87(9):1177-82; quiz 1287
pubmed: 16935051
J Epidemiol Glob Health. 2016 Sep;6(3):169-76
pubmed: 26599284
Clin Nurs Res. 2019 Mar;28(3):263-279
pubmed: 29103311
Int J Qual Health Care. 2011 Aug;23(4):405-12
pubmed: 21622716
Stroke. 2004 Oct;35(10):2340-5
pubmed: 15331799
Pharmacoepidemiol Drug Saf. 2020 May;29(5):538-549
pubmed: 32190948
J Stroke Cerebrovasc Dis. 2017 Aug;26(8):1689-1694
pubmed: 28416089
Circ Res. 2017 Feb 3;120(3):472-495
pubmed: 28154098
Neurol Res. 2020 Jul;42(7):537-546
pubmed: 32321382
J Comorb. 2016 Mar 4;6(2):35-41
pubmed: 29090170
Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):199-211
pubmed: 22458621
Ann Fam Med. 2012 Jan-Feb;10(1):6-14
pubmed: 22230825
Stroke. 2005 Jul;36(7):1480-4
pubmed: 15947263
Front Public Health. 2018 Jun 11;6:149
pubmed: 29942800
Lancet Neurol. 2009 Apr;8(4):308-9
pubmed: 19296917
Disabil Rehabil. 2002 Mar 20;24(5):259-65
pubmed: 12004971
Int J Hypertens. 2018 May 20;2018:3934296
pubmed: 29887993
Neurol India. 2007 Apr-Jun;55(2):130-5
pubmed: 17558116
Pediatr Infect Dis J. 2004 Nov;23(11):1035-41
pubmed: 15545859
Lancet. 2021 Sep 4;398(10303):841
pubmed: 34390658
Ann Intern Med. 2012 Dec 4;157(11):785-95
pubmed: 22964778
Am Heart J. 2016 May;175:130-41
pubmed: 27179732